Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Robbyn Tureman

Psychiatry Washington, DC Medical Doctor

NPI 1164621363 CMS profile 233944

2700 Martin Luther King Jr Ave Se, Washington, DC 20032

Open in the dashboard

General payments

$3,199

104 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Robbyn Tureman of Washington, DC is reported in the CMS Open Payments database as having received $3,199 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $43 2
2022 General $824 25
2021 General $179 9
2020 General $620 25
2019 General $1,533 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robbyn Tureman
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Robbyn Tureman were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Robbyn Tureman Psychiatry median Middle half National median
2019 $1,533 $184 $59–$605 $163
2020 $620 $119 $36–$372 $114
2021 $179 $143 $43–$576 $132
2022 $824 $153 $50–$590 $149
2023 $43 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Allergan Inc. $954 18 payments
  2. Sunovion Pharmaceuticals Inc. $842 41 payments
  3. Otsuka America Pharmaceutical, Inc. $550 14 payments
  4. Alkermes, Inc. $418 10 payments
  5. Teva Pharmaceuticals USA, Inc. $174 7 payments
  6. Lundbeck LLC $128 7 payments
  7. AbbVie, Inc. $59 3 payments
  8. Janssen Pharmaceuticals, Inc $43 2 payments
  9. Neurocrine Biosciences, Inc. $19 1 payment
  10. Vanda Pharmaceuticals Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,111 103 payments
  2. Education $88 1 payment
Products named General payments · program years 2019–2023
  1. VRAYLAR $954 18 payments
  2. LATUDA $842 41 payments
  3. ARISTADA Cns $418 10 payments
  4. ARISTADA Cns $418 10 payments
  5. ABILIFY MAINTENA $403 10 payments
  6. ARISTADA INITIO $393 9 payments
  7. ARISTADA Cns $290 4 payments
  8. ARISTADA Cns $290 4 payments
  9. REXULTI $262 10 payments
  10. LYBALVI $153 7 payments
  11. Other $372 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record